Richard Arlow

Cancer can be scary, but early detection is your greatest weapon. Mark Stovsky, MD MBA FACS of Cleveland Diagnostics, Inc., a leading expert in prostate cancer, shares 5 essential facts everyone should know: 1. 𝙄𝙣𝙩𝙚𝙡𝙡𝙞𝙜𝙚𝙣𝙩 𝙀𝙖𝙧𝙡𝙮 𝘿𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣 𝙞𝙨 𝙆𝙚𝙮: It's not just about catching it early, it's about using smarter methods like improved mammograms or better lung cancer scans. 2. 𝘾𝙝𝙤𝙤𝙨𝙚 𝙔𝙤𝙪𝙧 𝘿𝙤𝙘𝙩𝙤𝙧 𝙒𝙞𝙨𝙚𝙡𝙮: Find an expert specializing in your specific cancer type for access to cutting-edge treatments and testing. 3. 𝙁𝙞𝙣𝙙 𝙔𝙤𝙪𝙧 𝘾𝙤𝙢𝙢𝙪𝙣𝙞𝙩𝙮: Don't fight alone. Connect with loved ones and patient communities for support and resources. 4. 𝙍𝙚𝙘𝙚𝙣𝙩 𝘽𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙨 𝙖𝙧𝙚 𝙍𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙞𝙯𝙞𝙣𝙜 𝘾𝙖𝙣𝙘𝙚𝙧 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩: The last two decades have seen incredible advancements, offering much hope for the future. 5. 𝘾𝙖𝙣𝙘𝙚𝙧 𝙄𝙨𝙣'𝙩 𝙖 𝘿𝙚𝙖𝙩𝙝 𝙎𝙚𝙣𝙩𝙚𝙣𝙘𝙚: Early detection is crucial, but even with a diagnosis, there's a high chance of managing the disease and living a good life. Read the full interview with Dr. Stovsky in Authority Magazine: https://lnkd.in/dVFzPdea #Cancer #CancerSurvivor #ProstateCancer #EarlyDetection #CancerAwareness #Healthcare #Hope #PatientEmpowerment

14

Excellent article on how biotech investors approach early-stage asset due diligence—which unsurprisingly has strong parallels with how we approach late-stage asset diligence. Early-stage investors forecast the potential of these parameters to translate into clinical outcomes; late-stage investors evaluate the coalescence of these properties into the outcomes generated (and the likelihood that they can reproduce those outcomes). Great read for anyone evaluating or building a drug development program—thanks Aimee Raleigh and Atlas Venture #biotech #pharma #venturecapital #duediligence

33

3 Comments

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

6

This week, I explored the fascinating world of Targeted Alpha Therapy (TAT), an innovative form of radiotherapy that holds potential in cancer treatment. The scientific principles and investment trends are detailed in my latest article, "The Science Behind TAT: Precision, Power, and Promise."

6

According to the latest analysis from BiopharmIQ by Amp, Pennsylvania holds the #3 position in CGT ecosystems for companies with under 50 employees. However, as these companies grow, I hope they choose to mature in Philadelphia. Recently, I've had numerous conversations about the region's shortage of leadership/ executive talent. It's intriguing considering that 80% of Big Pharma is located within 90 miles of the city. What the CGT sector needs is more experienced leadership, and Big Pharma could serve as an excellent source for it. For the latest updates on Life Science and Biotech news in the Philadelphia region, join The Informal Philadelphia Life Science Group below!

3

Despite challenges in the IPO market in 2021, the biotechnology sector is resilient and showing signs of recovery. Tempus led the way last week. Congratulations to all stakeholders at Tempus! This period of turbulence urges biotech firms to strategically focus on building strong data foundations, which will not only attract investments but also pave the way for sustainable growth and innovation. Embracing uncertainty as an opportunity for innovation and skill development could redefine leadership in biotech, fostering a culture of resilience and adaptability crucial for sustained success in a rapidly evolving industry landscape. #Biotech #Leadership

19

Looking forward to this discussion with Ohio Life Sciences!

23

Invent Medical Corporation Receives the FDA 510(k) clearance for its HFT150® High Flow System Invent Medical Corporation is pleased to announce the FDA 510(k) clearance on their HFT150® high flow system. Sam Chang, CEO, comments, "After several years in development and based on multiple key opinion leaders' input on product design and features, we are launching the HFT150® high flow system, featuring patented proprietary platform technology into the USA hospital markets in the fall of 2024. Based on feedback from respiratory care practitioners and pulmonologists, we believe we have designed a world-class product that solves many of today's problems with current technologies in the high-flow market." A recent market report shows that the growth of the heated high-flow market sector is expected to outpace that of other respiratory devices. #inventrespiratory #highflowsystem #fdaclearance

60

38 Comments

By leveraging AI with vast genetic databases, we are not only quickening the pace of identifying potential drug targets but also enhancing the accuracy of clinical diagnostics and predictive modeling. Recently, I had the privilege of discussing the profound impact AI is having on pharmaceutical R&D with Kim Branson, GSK's SVP Global Head of Artificial Intelligence and Machine Learning. Listen on Raising Health: https://lnkd.in/g6QUm2-A

40

5 Comments

My colleague Stephen Pyke recently had the privilege of joining Dr. Tala Fakhouri from the FDA on Episode 2 of ACRO's Good Clinical Podcast. 🎙 They discussed the immense potential of AI in clinical research, delving into topics such as FDA's evidentiary standards for AI and the crucial role of methodological transparency in submissions. Stephen also weighs in on ACRO's AI/ML Principles Statement, an initiative he spearheaded as the Chair of the AI/ML Committee.   Access the episode on Apple Podcasts or Spotify. You can also stream it directly below. Enjoy ─ and let me know what you think in the comments! #ACRO #AIinHealthcare #ArtificialIntelligence

4

I am very proud of our team for accomplishing this. Connecting #RWD to the clinical and operational data we collect enables a stronger understanding of how participants respond to care. Access to medical information isn’t optional - it’s necessary and this provides that pathway towards precision care our industry sorely needs. Let’s go! #patientfirst, #humancentered, #simplybetterdata

24

1 Comment

Are you involved in the development of cell and gene therapies? The path to bringing these advanced therapies to market is markedly different from conventional drug development. Our upcoming webinar will delve into the complexities and challenges at various stages of development and provide phase-appropriate solutions to help you navigate this unique landscape. This webinar is brought to you by ATMP industrial consortium, supported by experts from various functional areas dedicated to advancing the field of cell and gene therapy. Using AAV as a real-world example, we will illustrate how the ATMP CoP has established guidelines and best practices across the industry.

9

As the American Society of Clinical Oncology (ASCO) 2024 meeting comes to a close, I am pleased to announce a major collaboration between NVIDIA and ConcertAI, to advance a broad set of oncology translational and clinical development solutions as part of ConcertAI's CARA AI platform. This partnership focuses on solutions for advanced inference and insight solutions in oncology research and treatment and will be supported by NVIDIA's deep AI expertise and advanced infrastructure. Going forward ConcertAI solutions will be integrating Meta Llama 3 NIMs, announced at Computex yesterday morning, to drive key LLM workloads inside ConcertAI's suite of solutions. The focus of ConcertAI's work with NVIDIA will be on large-scale clinical data processing, multi-agent models, clinical foundation models, and related solutions that enable domain-specific AI and broad application generative AI to interoperate with unprecedented precision. "AI offers incredible potential to transform how medicines are designed and developed, and bringing generative AI tools to improve clinical trials is a groundbreaking and necessary step," said Kimberly Powell, VP of Healthcare at NVIDIA. "Integrating NVIDIA's NIM's into ConcertAI's SaaS and extensive multi-modal data platform will revolutionize clinical trial design and outcome prediction." This collaboration underscores ConcertAI's commitment to harnessing the power of AI to drive innovation in healthcare and improve patient outcomes worldwide. Initial benefits from the collaboration will be accessible in the CARA AI cloud and solutions in Q3 of 2024. #NVIDIA #ConcertAI #AI #ASCO2024 #ASCO #precisiononcology #oncologytrials #oncologyresearch https://lnkd.in/eSFV2G44 #ConcertAI #AI #precisononcology #oncologytrials #oncologyresearch #NVIDIA

157

The proposed Biosecure Act aims to restrict U.S. reliance on Chinese contract research organizations like WuXi AppTec and BGI Group, impacting NIH-funded institutions and biotech firms that depend on them for research. This legislation could disrupt supply chains and R&D efforts crucial for drug development, highlighting vulnerabilities in outsourcing strategies within the pharmaceutical sector. I believe that embracing digital solutions such as chemical coding languages and date repos in molecule design and manufacturing could foster resilience, transforming how the industry navigates global supply chain challenges. #Biotech

13

2 Comments

Our GenAI for sequence and structure generation of paratopes in action

13

When clinicians, societies and industry collaborate you get magic! That is what all these people with #alzheimers deserve! More about our #ARIA developments to discover at the upcoming #ASNR meeting #weareicometrix

3

After multiple years of data collection, our study on the impact of engineering outreach efforts was published in the PLOS ONE journal. The findings offer an intriguing assessment of how collaborating with science-focused digital content creators like Mark Rober and Derek Muller (Veritasium) and engaging with the wider maker community can amplify the influence of a particular field of research. Whether you're in industry or academia, the goal of this publication is to help bridge the gap by sharing a framework for ways to better leverage novel academic research into applications in industry. https://lnkd.in/dpR6KjSF

32

2 Comments

Live from #ISCT2024. Dalip Sethi, PhD, MBA moderating the panel discussing “Can Process Analytical Technologies. (PATs) Really Improve Your CGT Manufacturing Process ?”

37